Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

FDA has approved new indications for Janssen's risperidone (Risperdal®) for treating schizophrenia in adolescents ages 13-17 and for the short-term treatment of manic or mixed episodes of bipolar 1 disorder in children and adolescents ages 10-17.

New FDA Approvals